192 related articles for article (PubMed ID: 22453662)
1. Design of novel BH3 mimetics for the treatment of chronic lymphocytic leukemia.
Billard C
Leukemia; 2012 Sep; 26(9):2032-8. PubMed ID: 22453662
[TBL] [Abstract][Full Text] [Related]
2. Development of Noxa-like BH3 mimetics for apoptosis-based therapeutic strategy in chronic lymphocytic leukemia.
Billard C
Mol Cancer Res; 2012 Jun; 10(6):673-6. PubMed ID: 22466256
[TBL] [Abstract][Full Text] [Related]
3. The first MCL-1-selective BH3 mimetics have therapeutic potential for chronic lymphocytic leukemia.
Besbes S; Pocard M; Mirshahi M; Billard C
Crit Rev Oncol Hematol; 2016 Apr; 100():32-6. PubMed ID: 26899021
[TBL] [Abstract][Full Text] [Related]
4. Hyperforin induces apoptosis of chronic lymphocytic leukemia cells through upregulation of the BH3-only protein Noxa.
Zaher M; Tang R; Bombarda I; Merhi F; Bauvois B; Billard C
Int J Oncol; 2012 Jan; 40(1):269-76. PubMed ID: 21947285
[TBL] [Abstract][Full Text] [Related]
5. BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells.
Pérez-Galán P; Roué G; López-Guerra M; Nguyen M; Villamor N; Montserrat E; Shore GC; Campo E; Colomer D
Leukemia; 2008 Sep; 22(9):1712-20. PubMed ID: 18596739
[TBL] [Abstract][Full Text] [Related]
6. Strategies targeting apoptosis proteins to improve therapy of chronic lymphocytic leukemia.
Besbes S; Mirshahi M; Pocard M; Billard C
Blood Rev; 2015 Sep; 29(5):345-50. PubMed ID: 25887155
[TBL] [Abstract][Full Text] [Related]
7. Small-molecule inhibitors of Bcl-2 family proteins are able to induce tumor regression in a mouse model of pre-B-cell acute lymphocytic lymphoma.
Turner BC; Eves T; Refaeli Y
DNA Cell Biol; 2008 Mar; 27(3):133-42. PubMed ID: 18163880
[TBL] [Abstract][Full Text] [Related]
8. BH3 mimetics: status of the field and new developments.
Billard C
Mol Cancer Ther; 2013 Sep; 12(9):1691-700. PubMed ID: 23974697
[TBL] [Abstract][Full Text] [Related]
9. Peptide screening to knockdown Bcl-2's anti-apoptotic activity: implications in cancer treatment.
Raghav PK; Verma YK; Gangenahalli GU
Int J Biol Macromol; 2012 Apr; 50(3):796-814. PubMed ID: 22155216
[TBL] [Abstract][Full Text] [Related]
10. Bcl-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cells.
Campàs C; Cosialls AM; Barragán M; Iglesias-Serret D; Santidrián AF; Coll-Mulet L; de Frias M; Domingo A; Pons G; Gil J
Exp Hematol; 2006 Dec; 34(12):1663-9. PubMed ID: 17157163
[TBL] [Abstract][Full Text] [Related]
11. A review of the role of Puma, Noxa and Bim in the tumorigenesis, therapy and drug resistance of chronic lymphocytic leukemia.
Zhang LN; Li JY; Xu W
Cancer Gene Ther; 2013 Jan; 20(1):1-7. PubMed ID: 23175245
[TBL] [Abstract][Full Text] [Related]
12. Targeting the intrinsic apoptosis pathway as a strategy for melanoma therapy.
Mohana-Kumaran N; Hill DS; Allen JD; Haass NK
Pigment Cell Melanoma Res; 2014 Jul; 27(4):525-39. PubMed ID: 24655414
[TBL] [Abstract][Full Text] [Related]
13. BCL2 Inhibitors as Anticancer Drugs: A Plethora of Misleading BH3 Mimetics.
S Soderquist R; Eastman A
Mol Cancer Ther; 2016 Sep; 15(9):2011-7. PubMed ID: 27535975
[TBL] [Abstract][Full Text] [Related]
14. New dimension in therapeutic targeting of BCL-2 family proteins.
Besbes S; Mirshahi M; Pocard M; Billard C
Oncotarget; 2015 May; 6(15):12862-71. PubMed ID: 25970783
[TBL] [Abstract][Full Text] [Related]
15. Reprogramming cell death: BCL2 family inhibition in hematological malignancies.
Scarfò L; Ghia P
Immunol Lett; 2013; 155(1-2):36-9. PubMed ID: 24095849
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and activity evaluation of broad-spectrum small-molecule inhibitors of anti-apoptotic Bcl-2 family proteins: characteristics of broad-spectrum protein binding and its effects on anti-tumor activity.
Zheng CH; Yang H; Zhang M; Lu SH; Shi D; Wang J; Chen XH; Ren XH; Liu J; Lv JG; Zhu J; Zhou YJ
Bioorg Med Chem Lett; 2012 Jan; 22(1):39-44. PubMed ID: 22172701
[TBL] [Abstract][Full Text] [Related]
17. The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs.
High LM; Szymanska B; Wilczynska-Kalak U; Barber N; O'Brien R; Khaw SL; Vikstrom IB; Roberts AW; Lock RB
Mol Pharmacol; 2010 Mar; 77(3):483-94. PubMed ID: 20038611
[TBL] [Abstract][Full Text] [Related]
18. Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737.
Lucas KM; Mohana-Kumaran N; Lau D; Zhang XD; Hersey P; Huang DC; Weninger W; Haass NK; Allen JD
Clin Cancer Res; 2012 Feb; 18(3):783-95. PubMed ID: 22173547
[TBL] [Abstract][Full Text] [Related]
19. Aspirin induces apoptosis in human leukemia cells independently of NF-kappaB and MAPKs through alteration of the Mcl-1/Noxa balance.
Iglesias-Serret D; Piqué M; Barragán M; Cosialls AM; Santidrián AF; González-Gironès DM; Coll-Mulet L; de Frias M; Pons G; Gil J
Apoptosis; 2010 Feb; 15(2):219-29. PubMed ID: 19936928
[TBL] [Abstract][Full Text] [Related]
20. Subversion of the Bcl-2 life/death switch in cancer development and therapy.
Adams JM; Huang DC; Strasser A; Willis S; Chen L; Wei A; van Delft M; Fletcher JI; Puthalakath H; Kuroda J; Michalak EM; Kelly PN; Bouillet P; Villunger A; O'Reilly L; Bath ML; Smith DP; Egle A; Harris AW; Hinds M; Colman P; Cory S
Cold Spring Harb Symp Quant Biol; 2005; 70():469-77. PubMed ID: 16869785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
